Interventions for preventing neuropathy caused by cisplatin and related compounds

Albers, James W.; Chaudhry, Vinay; Cavaletti, Guido; Donehower, Ross C.

doi:10.1002/14651858.cd005228.pub2

Cited by 40 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy, so far no drug or nutritional supplement has been shown to be capable of preventing or limiting chemotherapy-induced neuropathy, highlighting the relevance to opportunely detect and treat this complication in children with leukemia (11). To our knowledge, there is no previous report on the frequency and type of CIPN in Mexican children with ALL.…”

Section: Introductionmentioning

confidence: 93%

Chemotherapy-Induced Peripheral Neuropathy in a Subpopulation of Mexican Pediatric Patients with Acute Lymphoblastic Leukemia

et al. 2017

View full text Add to dashboard Cite

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is frequent in children with acute lymphoblastic leukemia (ALL). Neurological manifestations can be grouped into one of the three functional divisions of the peripheral nervous system (PNS): sensory, motor and autonomic. One of the chemotherapeutic agents used in ALL is vincristine which has been associated with neuropathy in these children. This type of neuropathy can be transient but also leave permanent sequels that decrease patient's quality of life. Objectives: To know the frequency and type of neuropathy induced by chemotherapy in a subpopulation of Mexican pediatric patients with acute lymphoblastic leukemia. Methods: A cross-sectional study was conducted. There were included all pediatric patients with ALL diagnosed de novo from 2010 to December 31, 2013 who met the selection criteria. Descriptive statistics were used to determine the frequency and type of CIPN and information was described according to different clinical variables, type of treatment, risk classification, and ALL subtype according to the immunophenotype. Results: A total of 32 patients with acute lymphoblastic leukemia were included, mainly of early pre-B immunophenotype (93.8%), being 59.4% classified as high risk patients at the time of diagnosis. CIPN of sensory type was 78.1%, motor 34.3% and autonomic 40.6%. A significant proportion of patients (46.9%) were examined during maintenance phase. Conclusions: To our knowledge, this is the first study to report the frequency and type of CIPN in a subpopulation of Mexican children with acute lymphoblastic leukemia. Frequency of CIPN was higher than that reported in other populations. By considering that prognosis of a patient presenting CIPN could be considered as favorable after treatment suspension (in most cases), it is not always reversible and affects patient's quality of life. Therefore, it is necessary for all patients with ALL to be periodically monitored during treatment through neurological examination for detecting and immediately initiating their rehabilitation treatment.

show abstract

Section: Introductionmentioning

confidence: 93%

Chemotherapy-Induced Peripheral Neuropathy in a Subpopulation of Mexican Pediatric Patients with Acute Lymphoblastic Leukemia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Neuropathic pain resulting from peripheral neuropathy does not respond as well to opioids and may require other management strategies that employ antidepressants or anticonvulsants [51]. Preventative therapies have also been investigated but with questionable success rates.…”

Section: Symptom Managementmentioning

confidence: 99%

Health-related quality of life in ovarian cancer patients and its impact on clinical management

Chase

Wenzel

2011

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Although the incidence of ovarian cancer is less than that of other female cancers, the morbidity and mortality associated with the disease course is high. Because treatment involves radical surgery and intense courses of chemotherapy, health-related quality of life (HRQOL) is often compromised. Most patients recur post-first-line therapy and undergo multiple rounds of chemotherapy. Thus, HRQOL is further disrupted. As the ongoing search for optima therapies in both the first-line and recurrent setting continues, much attention is paid towards clinical trial design and implementation. Over the last decade, patient-reported outcomes and HRQOL measurement have become an integral part of these trials. HRQOL data are valued in examining the extent of treatment benefit and therefore can aid in decision-making during active treatment and palliative care. HRQOL and patient-reported outcome measurement is also useful in determining symptom prevalence, severity and management. This article highlights the state of the science of HRQOL measurement in clinical trial design and outcomes. In addition, symptom management in ovarian cancer and its ability to modulate quality of life will be explored.

show abstract

“…A 2011 Cochrane review examined the literature on a wide range of chemoprotective agents for cisplatin neurotoxicity, and concluded that no such agent had been identified in a high quality clinical trial [24]. …”

Section: Discussionmentioning

confidence: 99%

Lhermitte's Phenomenon and Platinum, Beware of Latency

O’Reilly

Ryan²,

MacEneaney³

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

SummaryBackground: Lhermitte's sign (LS) is characterized by electric shock-like sensations, spreading along the spine in a cervico-caudal direction and into the arms and legs. It is felt upon flexion of the neck and reflects a myelopathy resulting from damage to sensory axons at the dorsal columns of the cervical spinal cord. In patients with cancer, LS can occur due to direct tumour involvement of the spine or in relation to radiotherapy. Chemotherapy-related LS has only rarely been reported. Case Report: We present the case of a 44-year-old patient treated with platinum- and etoposide-based chemotherapy for metastatic seminoma, who subsequently developed severe disabling LS. The severity and duration of LS in this case exceeds prior reports. We review the literature on chemotherapy-related LS and discuss the practice implications. Conclusion: Neuropathy and LS related to cisplatin-based chemotherapy can result in significant adverse effects. Raised awareness of this complication could aid sub-phenotyping of the population most at risk and assist strategies to avert discomfort and disability post chemotherapy.

show abstract

Interventions for preventing neuropathy caused by cisplatin and related compounds

Cited by 40 publications

References 45 publications

Chemotherapy-Induced Peripheral Neuropathy in a Subpopulation of Mexican Pediatric Patients with Acute Lymphoblastic Leukemia

Chemotherapy-Induced Peripheral Neuropathy in a Subpopulation of Mexican Pediatric Patients with Acute Lymphoblastic Leukemia

Health-related quality of life in ovarian cancer patients and its impact on clinical management

Lhermitte's Phenomenon and Platinum, Beware of Latency

Contact Info

Product

Resources

About